Curtis M Chan

TL;DR: It is shown that adeno-associated virus (AAV) 9 injected intravenously bypasses the BBB and efficiently targets cells of the central nervous system (CNS) and may enable the development of gene therapies for a range of neurodegenerative diseases.

TL;DR: CSF injection efficiently targeted motor neurons, and restricted gene expression to the CNS, providing an alternate delivery route and potentially lower manufacturing requirements for older, larger patients, and support the use of AAV9 for gene transfer to the central nervous system for disorders in pediatric populations.

TL;DR: Tissue cross-reactivity studies are screening assays recommended for antibody and antibody-like molecules that contain a complementarity-determining region (CDR), primarily to identify off- target binding and, secondarily, to identify sites of on-target binding that were not previously identified.

TL;DR: This study further validates convection-enhanced delivery (CED) as the preferred method of viral vector delivery to the brain, and supports a Phase I clinical testing of AAV2-hAADC in humans with Parkinson's disease.

TL;DR: Data show that Ct values likely do not provide a consistent proxy for infectiousness across SARS-CoV-2 variants, and among specimens with culturable virus detected, Ct values were higher during Omicron BA.1.1 infections than during pre-Omicron infections, suggesting variant-specific differences in viral dynamics.